Report Id: SNS/HC/1011 | May 2022 | Region: Global | 125 Pages
Report Scope & Overview:
Artificial intelligence in drug discovery market is projected to arrive at USD 5632 million by 2028 from USD 513 million of every 2021, at a CAGR of 40.8% during the gauge time frame 2022-2028. The development of the man-made brainpower in drug revelation market is fundamentally determined by elements like the developing number of cross-industry coordinated efforts and associations, the rising need to control drug disclosure and improvement costs and lessen the general time taken in this interaction, the rising reception of cloud-based applications and administrations, and the approaching patent expiry of blockbuster drugs.
Then again, an absence of informational collections in the field of medication disclosure and the deficient accessibility of gifted work are a portion of the elements testing the development of the market. Man-made reasoning has huge applications in the medication revelation field as it helps track sicknesses, make illness fixes and foresee which creature infections seem to transform. Man-made consciousness has been known to upgrade R&D in drug disclosure, which has assisted analysts with finding constant illness medicines. Drug disclosure and advancement in the fields of medication, pharmacology, and biotechnology are processes for the creation, plan, and acquisition of a medication through distinguishing a natural objective, like catalyst protein, quality, or receptor. Beforehand, the medications were found by distinguishing the dynamic fixing regular medicines. Subsequently, drug disclosure is the initial phase during the time spent distinguishing possible novel medications and their restorative reason. New standards for drugs are estimated in light of their bioavailability, adequacy, power, and poisonousness.
Impact of COVID on artificial intelligence for drug discovery
It is assessed that computerized reasoning for drug revelation and advancement market would show a critical market development because of the Covid-19 pandemic, inferable from ascending in the reception of AI to find and foster medications for treatment of COVID-19. For example, in June 2020 Repurpose.AI teamed up with Scripps Research to foster COVID-19 therapeutics with an emphasis on drug reusing. Man-made reasoning based drug screening strategies will hypothetically assist with making sense of significant pieces of the infection, (for example, protein structure) to survey how the elements of the infection can assume a fundamental part in a drug plan and speed up antibody advancements to battle COVID-19. Besides, Artificial knowledge can help drug disclosure and advancement process by rapidly recognizing drugs having viability against COVID-19. This overcomes any issues between a number of reused drugs (involving existing medications for different illnesses), clinical testing, and the last medication approval process.
The product section represented the biggest portion of the AI in the medication revelation market, by type, in 2021
In view of offering, the man-made brainpower in the medication disclosure market is sectioned into programming and administration. In 2020, the product fragment represented a bigger portion of the overall industry during the conjecture time frame. Factors, for example, less expense and time to advertise the medication, low disappointment rate, an enormous number of programming engineers for drug disclosure, and solid interest for the product among large pharma and biotech organizations and examination foundations are driving the development of the product fragment.
The neurodegenerative illnesses section is supposed to develop at the most elevated CAGR during the gauge time frame.
In view of the application, the computerized reasoning in the medication disclosure market is divided into neurodegenerative sicknesses, immuno-oncology, cardiovascular illness, metabolic infections, and different applications. Neurodegenerative illnesses structure the quickest developing application fragment, with a most noteworthy CAGR during the estimated time frame. The capacity of AI to find drugs for complex circumstances and the accentuation of market players on giving AI-based stages to neurological illnesses are liable for the quick development of this application portion.
The drug and biotechnology organizations portion represented the biggest portion of the AI in the medication disclosure market in 2021
In light of end-client, the AI in the medication disclosure market is sectioned into drug and biotechnology organizations, contract research associations, examination focuses, and scholarly, and government establishments. In 2018, the drug and biotechnology organizations section represented the biggest offer in the AI in the medication disclosure market.
North America represented the biggest portion of the AI in the medication revelation market in 2021
The worldwide AI in the medication disclosure market is sectioned into four significant areas, specifically, North America, Europe, APAC, and the Rest of the World. In 2022, North America was the biggest and the quickest developing provincial market for AI in drug revelation. North America, which involves the US, Canada, and Mexico, frames the biggest market for AI in drug disclosure. These nations have been early adopters of AI innovation in drug disclosure and advancement. In the North American market, the US is a significant supporter. Likewise, unmistakable AI innovation suppliers, like IBM, Google, Microsoft, NVIDIA, and Intel, are settled in the US; their solid presence is a critical supporter of market development. Different drivers incorporate the deep-rooted drug industry, high spotlight on R&D and significant speculation, and the presence of worldwide driving drug organizations. These are a portion of the central point answerable for the huge offer and high development pace of this market.
Key players in the AI in the drug discovery market
The AI in the medication revelation market is divided in nature, with an enormous number of players, including level 1, mid-level organizations, and startup firms, going after portions of the overall industry. The conspicuous players in the worldwide AI in drug revelation market incorporate IBM Corporation, Microsoft, and Google, NVIDIA Corporation, Atomwise, Inc., Deep Genomics, Cloud Pharmaceuticals, Insilico Medicine, BenevolentAI, Exscientia, Cyclica, BIOAGE, Numerate, NuMedii, Envisagenics, twoXAR, OWKIN, Inc., XtalPi, Verge Genomics, and BERG LLC.
KEY MARKET SEGMENTS:
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Academic & Government Institutes
Excavation and mining
North America held the major man-made consciousness for drug disclosure and improvement portion of the overall industry in 2021 and is supposed to proceed with its strength during the estimated time frame, attributable to solid economies like the U.S. furthermore, Canada; high reception pace of AI innovations because of an enormous number of speculations to support the medication disclosure industry; and a huge number of cross-industry joint efforts and associations, which significantly fuel the market development. Be that as it may, Asia-Pacific is supposed to develop at the most noteworthy CAGR during the estimated time frame, inferable from ascending in the reception of cutting edge AI advancements and development in the focal point of central parts on expanding their presence in arising Asian nations.
Exhaustive cutthroat examination and profiles of the major man-made consciousness for drug revelation and improvement market players like Alphabet Inc., Atomwise, Inc., Benevolent AI, Cloud Pharmaceutical, Deep Genomics, Exscientia, IBM Corporation, Insilico Medicine Inc., Microsoft Corporation, and Nvidia Corporation are given in this report.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2021||US$ 513 Million|
|Market Size by 2028||US$ 5632 Million|
|CAGR||CAGR of 40.8% From 2022 to 2028|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Components (software and service)
• By Technology (Machine learning, deep learning, Supervised Learning, Reinforcement Learning, Unsupervised Learning, Others)
• By Application
• By End Use
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||IBM Corporation, Microsoft, and Google, NVIDIA Corporation, Atomwise, Inc., Deep Genomics, Cloud Pharmaceuticals, Insilico Medicine, BenevolentAI, Exscientia, Cyclica, BIOAGE, Numerate, NuMedii, Envisagenics, twoXAR, OWKIN, Inc., XtalPi, Verge Genomics, and BERG LLC.|
Frequently Asked Questions (FAQ) :
Ans. Manufacturer and service provider, research institutes, university and private libraries, suppliers and distributers.
Ans. Neurodegenerative diseases, immuno-oncology, cardiovascular diseases, and metabolic diseases form AI in the drug discovery industry. Due to the growing demand for effective cancer treatment, the immuno-oncology segment holds the highest share of AI in the drug discovery market.
Ans. North America has the largest market share in AI in Drug Discovery Market.
Ans. The drivers of AI in Drug Discovery Market include Increasing Adoption of Artificial Intelligence in Healthcare Sector and growing Investment in Healthcare Sector
Ans. The Global Artificial Intelligence in Diagnostics Market is estimated to reach $162.9billion by 2028.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID 19 Impact Analysis
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. The SNS Graph
9. Artificial Intelligence in Drug Discovery Market Segmentation,by Component
10. Artificial Intelligence in Drug Discovery Market Segmentation, by technology
10.1 Machine Learning
10.2 Deep Learning
10.3 Supervised Learning
10.4 Reinforcement Learning
10.5 Unsupervised Learning
10.7 Others Technologies
11 .Artificial Intelligence in Drug Discovery Market Segmentation, By end use
11.1 Pharmaceutical & Biotechnology Companies
11.2 Contract Research Organizations
11.3 Research Centres
11.4 Academic & Government Institutes
12. Artificial Intelligence in Drug Discovery Market Segmentation, By application
12.1Excavation and mining
12.3 Neurodegenerative Diseases
12.4 Cardiovascular Diseases
12.5 Metabolic Diseases
13. Regional Analysis
13.2 North America
13.3.6 The Netherlands
13.3.7 Rest of Europe
13.4.2 South Korea
13.4.6 Rest of Asia-Pacific
13.5 The Middle East & Africa
13.5.3 South Africa
13.6 Latin America
13.6.3 Rest of Latin America
14. Company Profiles
14.1.2 Products/ Services Offered
14.1.3 SWOT Analysis
14.1.4 The SNS view
14.2 AB VOLVO
14.3 CATTERPILLAR INC.
14.4 CNH INDUSTRIAL N.V
14.5 DEERE AND COMPANY
14.6 DOOSAN INFRACOE CO.LTD
14.7 J C BAMFORD EXCAVATORS. LTD.
14.8 KOMATSU LTD.
14.9 Liebherr-international AG
14.10 XCMG GROUP
15. Competitive Landscape
15.1 Competitive Benchmarking
15.2 Market Share analysis
15.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.